Answers are grounded in this paper and cite their sources.
After 25 years and two unsuccessful Phase III trials, the elusive goal of an effective HIV vaccine receded further when the Phase IIb STEP study was curtailed upon reaching predetermined futility criteria. Analyses to date suggest that the vaccine regimen successfully engendered HIV-specific T-lymphocyte responses. Yet this was at best ineffective, as the group of male subjects with prior immunity to adenovirus-5 appeared to have an increased risk of infection. With the vaccine development pipeline entirely focused on eliciting cell-mediated immunity, and many candidates incorporating recombinant adenoviral vectors, the failure of STEP issues a strong challenge to HIV vaccine scientists on several fronts. Can a vaccine provoking cell-mediated immunity protect against HIV? Does prior immunity to a vaccine vector render it ineffective or even dangerous? And how do we identify the next Phase III vaccine candidate when in vitro immunogenicity and apparent protection in animal models has failed to predict success in humans?
No takes yet. Share an insight, caveat, or question.
Weatherall et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: